Silvana Capalbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silvana Capalbo has a total of 281 co-authors. Here are the top co-authors by number of shared publications:
Vincenzo Liso
Hematology Section, Department of Internal Medicine and Public Medicine, University of Bari, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy
12 shared publications- Giorgina Specchia
School of Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
11 shared publications - Mario Delia
Hematology and Stem Cell Transplantation Unit, Azienda Ospedaliero Universitaria Consorziale Policlinico, 70124, Bari, Italy
7 shared publications Daniela Diomede
Hematology Section, Department of Internal Medicine and Public Medicine, University of Bari, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy
6 shared publicationsGaetano Palumbo
Department of Hematology, "Riuniti" Hospital, 71100 Foggia, Italy
6 shared publicationsNicola Cascavilla
D Unit of Hematology and Bone Marrow Transplantation 'Casa Sollievo Della Sofferenza' S. Giovanni Rotondo , Foggia , Italy
6 shared publications
Latest Publications
- Open Access
- 28 July 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (10) , 1200-1207
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients
The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia patients in early chronic phase. A deep molecular response was achieved in 46% (MR4.0) and 17% (MR4.5) of patients at 2 years; 58% of the enrolled patients achieved a MR4.0 at least once, with a sustained MR4.0 in 52% of them. With a median observation of 29 months (range 24–37 months), 77% of patients were still on treatment with nilotinib. The reasons for permanent discontinuation were: 3% progression, 5% failure or suboptimal response, 8% adverse events, 1% treatment-free remission, and 5% other reasons. Thirteen thrombotic arterial events were reported in 12 patients. A prospective evaluation of metabolic effects showed an increase of fasting glucose without significant variations of glycated hemoglobin, an increase of total cholesterol (both low density lipoprotein and high density lipoprotein fractions) and a decrease of triglycerides. This study confirms a high and rapid efficacy of nilotinib 300 mg twice daily and provides detailed information on the type and incidence of non-hematologic and metabolic adverse events (clinicaltrials.gov identifier: 01535391).
- 28 July 2016
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (10) , 1200-1207
Open AccessNilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients
The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia patients in early chronic phase. A deep molecular response was achieved in 46% (MR4.0) and 17% (MR4.5) of patients at 2 years; 58% of the enrolled patients achieved a MR4.0 at least once, with a sustained MR4.0 in 52% of them. With a median observation of 29 months (range 24–37 months), 77% of patients were still on treatment with nilotinib. The reasons for permanent discontinuation were: 3% progression, 5% failure or suboptimal response, 8% adverse events, 1% treatment-free remission, and 5% other reasons. Thirteen thrombotic arterial events were reported in 12 patients. A prospective evaluation of metabolic effects showed an increase of fasting glucose without significant variations of glycated hemoglobin, an increase of total cholesterol (both low density lipoprotein and high density lipoprotein fractions) and a decrease of triglycerides. This study confirms a high and rapid efficacy of nilotinib 300 mg twice daily and provides detailed information on the type and incidence of non-hematologic and metabolic adverse events (clinicaltrials.gov identifier: 01535391).
- 3 June 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (11) , 4487-4493
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis
- 3 June 2016
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (11) , 4487-4493
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis
- 31 May 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (1) , 138-144
Ruxolitinib – better prognostic impact in low-intermediate 1 risk score: evaluation of the ‘rete ematologica pugliese’ (REP) in primary and secondary myelofibrosis
We evaluated ruxolitinib in 65 patients with myelofibrosis according to age, sex, time of diagnosis, grade of fibrosis, prognostic score risk, Janus kinase (JAK) status, primary or secondary myelofibrosis, previous treatment, and dosage. Outcome measures were response rate, time to response, duration of response, and event-free survival and survival. Kaplan and Meier curves show a significant difference in event-free survival according to the prognostic score, in favor of patients with low int1 (p = 0.0009). The Cox stepwise model confirmed the result, the int2 high-risk score being the most powerful negative independent parameter (0.001), followed by JAK (0.008); other parameters, such as diagnosis more than 5 years earlier, grade III–IV fibrosis, and ruxolitinib dose have a negligible impact. Time to response was shorter (p = 0.001) in primary myelofibrosis. In conclusion, ruxolitinib is effective, with a better outcome in patients with a low-int1 risk score. This may suggest considering an earlier administration in the disease course.
- 31 May 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (1) , 138-144
Ruxolitinib – better prognostic impact in low-intermediate 1 risk score: evaluation of the ‘rete ematologica pugliese’ (REP) in primary and secondary myelofibrosis
We evaluated ruxolitinib in 65 patients with myelofibrosis according to age, sex, time of diagnosis, grade of fibrosis, prognostic score risk, Janus kinase (JAK) status, primary or secondary myelofibrosis, previous treatment, and dosage. Outcome measures were response rate, time to response, duration of response, and event-free survival and survival. Kaplan and Meier curves show a significant difference in event-free survival according to the prognostic score, in favor of patients with low int1 (p = 0.0009). The Cox stepwise model confirmed the result, the int2 high-risk score being the most powerful negative independent parameter (0.001), followed by JAK (0.008); other parameters, such as diagnosis more than 5 years earlier, grade III–IV fibrosis, and ruxolitinib dose have a negligible impact. Time to response was shorter (p = 0.001) in primary myelofibrosis. In conclusion, ruxolitinib is effective, with a better outcome in patients with a low-int1 risk score. This may suggest considering an earlier administration in the disease course.
- 20 August 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (11) , 1166-1171
Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP)
- 20 August 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (11) , 1166-1171
Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP)
- 1 February 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (2) , 138-143
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression
- 1 February 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (2) , 138-143
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression
- 1 January 2015
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 16, S65
Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab
- 1 January 2015
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 16, S65
Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab
- 1 October 2013
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 170 (2) , 576-577
Management of platelet storage pool disease during pregnancy with recombinant factor VIIa
- 1 October 2013
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 170 (2) , 576-577
Management of platelet storage pool disease during pregnancy with recombinant factor VIIa
- 1 August 2013
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 6 (4) , 441-449
Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need
- 1 August 2013
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 6 (4) , 441-449
Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need
- Open Access
- 1 August 2013
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 19 (8) , 757-762
Hema e-Chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections
- 1 August 2013
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 19 (8) , 757-762
Open AccessHema e-Chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections